1 day ago
3
Soumya Eswaran
Fri, June 12, 2026 astatine 9:28 AM CDT 4 min read
Guinness Global Innovators, an concern absorption company, precocious released its Q1 2026 quarterly capitalist update for its “Guinness Global Equity Income Fund”. A transcript of the missive is disposable to download here. The Fund focuses connected providing investors with planetary vulnerability to dividend-paying companies. In Q1 2026, the money returned was -0.5% (GBP), compared to -1.6% for the MSCI World Index and 0.1% for the IA Global Equity Income assemblage average. The 4th saw notable changes successful marketplace sentiment driven by geopolitical tensions and vigor marketplace disruptions. The marketplace shifted absorption from maturation sectors, peculiarly mega-cap exertion and software, to value-oriented, defensive, international, and ‘physical economy’ stocks. The Fund gained from this modulation towards antiaircraft and worth areas successful the quarter. The missive discusses the interaction of macro events and marketplace dynamics connected Q1 show and examines bundle manufacture valuations amid rising concerns astir AI-driven disruption. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.
In its first-quarter 2026 capitalist letter, Guinness Global Equity Income Fund highlighted stocks similar Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) is simply a starring planetary healthcare institution that engages successful the probe and development, manufacture, and merchantability of a scope of products successful the healthcare field. On June 11, 2026, Johnson & Johnson (NYSE:JNJ) closed astatine $238.33 per share. One-month instrumentality of Johnson & Johnson (NYSE:JNJ) was 5.13%, and its shares gained 51.71% implicit the past 52 weeks. Johnson & Johnson (NYSE:JNJ) has a marketplace capitalization of $573.71 billion.
Guinness Global Equity Income Fund stated the pursuing regarding Johnson & Johnson (NYSE:JNJ) successful its Q1 2026 capitalist letter:
"Johnson & Johnson (NYSE:JNJ) was the Fund’s top-performing banal successful Q1 2026, rising 18.7% arsenic markets gained assurance that the institution has been efficaciously replacing revenues of Stelara, a cause that accounted for much than 10% of income astatine its peak, but ‘loss of exclusivity’ led to galore biosimilar launches successful 2025. That assurance was fuelled by a precise coagulated net people with which the steadfast reported full-year income maturation of 6%, contempt a 7.5 percent constituent headwind from Stelara’s nonaccomplishment of exclusivity. Organic income maturation accelerated significantly, rising from 3.7% successful Q3 (and 2.4% successful Q2) to 7.9% successful Q4. Performance was broad-based, with beardown momentum crossed a fig of cardinal drugs wrong the firm’s pharma division, with Tremfya (Crohn’s disease) and Darzalex (Myeloma) the stand-outs. Alone, these drugs were capable to supply $4.2bn successful income growth, astir afloat offsetting the $4.3bn diminution from Stelara. The remaining drugs successful the pharma portfolio were capable to turn different $3.6bn, a 6% publication to the wide maturation of the pharma division. MedTech was likewise encouraging, with income up of statement by 40 ground points and spot crossed Orthopaedics (recently spun out), Surgery, and Vision, supported by the firm’s caller Shockwave acquisition. Importantly, absorption reiterated coagulated 2026 guidance astatine 5.9% (at the mid-point), and reiterated assurance successful achieving the precocious extremity of its 5-7% semipermanent income maturation target, with a credible way to double-digit maturation aboriginal successful the decade, benefitting from the roll-off of patent cliff headwinds..." (Click present to work the afloat text)
English (CA) · 
English (US) · 
Spanish (MX) ·